Toutes les études
Actif, mais pas en recrutementPHASE3INTERVENTIONNEL

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

This research study is looking for adults with a bleeding disorder called primary Immune Thrombocytopenia (ITP). ITP causes your body to wrongly attack and destroy your platelets, which are tiny cells that help your blood clot. If your ITP hasn't gotten better after trying steroid medication, this study might be for you. The study aims to find out if adding a new drug, ianalumab, to an existing treatment called eltrombopag, can help keep your platelet count at a healthy level for a longer time. They also want to see how safe this combination of drugs is. Participants will receive either ianalumab or a placebo (a dummy drug) along with eltrombopag, and will be carefully monitored throughout the study.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE3
Sponsor
Novartis Pharmaceutiques
Objectif d'inscription
152
Démarrer
02 Feb 2023
Achèvement estimé
08 Apr 2028

De quoi parle cette étude ?

Imagine your body's immune system as a protective shield. In primary Immune Thrombocytopenia (ITP), this shield mistakenly attacks your own platelets, which are crucial for stopping bleeding. When your platelet count drops too low, you can bruise easily or experience more serious bleeding problems. The usual first step to treat ITP is often steroid medication, but for many people, steroids don't work well or their ITP comes back.

This study is looking for a better way to help people whose ITP hasn't responded to steroids. It's focusing on a new drug called ianalumab, which is being tested alongside eltrombopag, a medication already approved for ITP. Eltrombopag works by encouraging your body to make more platelets. Researchers want to see if adding ianalumab can make eltrombopag even more effective at keeping platelet counts stable and preventing the need for other treatments or worsening symptoms. They also want to make sure the combination is safe.

The study is designed to be fair and unbiased. Half of the participants will receive ianalumab plus eltrombopag, and the other half will receive a placebo (dummy drug) plus eltrombopag. Neither you nor your doctor will know which treatment you are receiving, which helps ensure the results are as accurate as possible. This is a common and important way that medical research is done.

Points clés

  • New study for adults with ITP not helped by steroids.
  • Compares ianalumab with placebo, both given with eltrombopag.
  • Aims to keep platelet counts stable for longer and check safety.
  • Participation involves regular check-ups and blood tests.
  • You won't know if you're getting ianalumab or the placebo (double-blind).
  • Vous pouvez arrêter de participer à tout moment.

Qui peut être éligible ?

To join this study, you need to be an adult (18 years or older) with a diagnosis of primary ITP. Your ITP must not have responded well to, or may have come back after, treatment with steroids. Your current platelet count needs to be quite low (below 30), and your doctor should agree that eltrombopag is a suitable treatment for you.

There are also some important reasons why you *wouldn't* be able to join. For example, if you've already had multiple treatments for your ITP (other than steroids), including surgery to remove your spleen, this study might not be right for you. They are focusing on people whose first-line steroid treatment hasn't worked.

Other reasons for not being able to join include having certain other serious health conditions like specific blood disorders, severe infections, active liver problems, or being pregnant or breastfeeding. The researchers want to make sure the study is safe for everyone involved and that the results are clear for those who fit the specific criteria.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Have you been diagnosed with primary ITP?
  3. Has your ITP not responded well to, or come back after, steroid treatment?
  4. Is your current platelet count lower than 30? (Your doctor can confirm this).
  5. Have you had your spleen removed or undergone other major ITP treatments (apart from steroids/IVIG)? (If yes, you might not be eligible).
  6. Are you pregnant or breastfeeding, or do you have any serious underlying health conditions like severe liver problems or uncontrolled infections? (If yes, you might not be eligible).
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you'll first have a screening period where doctors will check if the study is right for you. Then, you'll be randomly assigned to one of two groups: one receiving ianalumab plus eltrombopag, and the other receiving a placebo (a dummy drug) plus eltrombopag. You'll take these medications for a certain period. After that, your eltrombopag dose might be slowly reduced while still being monitored.

Once the main treatment period is over, you'll enter a follow-up phase. During this time, the study team will continue to check your health, blood counts, and response to treatment. This is important to understand how the medicines worked in the long term and to ensure your safety. The total duration of your participation will vary depending on how you respond and how long the researchers need to follow your progress, but it will involve regular clinic visits to monitor your health and take blood samples.

Risques et avantages potentiels

Taking part in any medical study has potential benefits and risks. You might benefit from closer medical attention and potentially receive a new treatment that could improve your ITP if ianalumab is effective. However, there's no guarantee the treatment will work for you, and it might not be better than standard treatments. There could also be side effects from the study drugs, some of which are currently unknown, or you might find the frequent clinic visits inconvenient. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (74)

  • Yuma Regional Medical Center
    Code postal vérifié
    Yuma, United States
  • University of Colorado Anschutz
    Code postal vérifié
    Aurora, États-Unis
  • Endeavor Health
    Code postal vérifié
    Evanston, United States
  • Boston Medical Center
    Code postal vérifié
    Boston, États-Unis
  • UMASS Memorial Medical Center
    Code postal vérifié
    Worcester, United States
  • Michigan Center of Medical Research
    Code postal vérifié
    Farmington Hills, United States
  • St Vincent Frontier Cancer Center
    Code postal vérifié
    Billings, United States
  • Hematology Oncology Association of Rockland
    Code postal vérifié
    Nyack, United States
  • Centre Médical Montefiore
    Code postal vérifié
    Le Bronx, États-Unis
  • Site d'Investigation Novartis
    Non vérifié
    CABA, Argentina
  • Site d'Investigation Novartis
    Code postal vérifié
    Vienne, Autriche
  • Site d'Investigation Novartis
    Code postal vérifié
    Yvoir, Belgium

Questions fréquentes

What is ITP?

ITP stands for Immune Thrombocytopenia. It's a blood condition where your body's immune system mistakenly attacks and destroys your platelets, which are important for blood clotting.

Qu'est-ce qu'un 'placebo' ?

A placebo is a 'dummy drug' that looks exactly like the real medication but doesn't contain any active ingredients. It's used in studies to compare the new drug's effects against having no active treatment.

Does this study mean I stop my current ITP treatment?

The study is for people whose ITP hasn't improved with steroids. You would receive eltrombopag, an existing ITP treatment, plus either the new drug (ianalumab) or a placebo. Your doctors will discuss your current treatment plan with you.

Combien de temps vais-je participer à l'étude ?

The exact duration can vary, as it depends on your response to treatment and the study design. It will involve a treatment period followed by a follow-up period to monitor your health and response.

Puis-je quitter l'étude à tout moment ?

Yes, you are free to withdraw from the study at any point, for any reason, without it affecting your current or future medical care.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.